Rockville-based biotech company MacroGenics filed for a $60 million initial public offering on Sept. 4.
The Washington Business Journal reports:
MacroGenics, a clinical-stage biotech focused on oncology, said it would use the proceeds to fund clinical development for margetuximab (also known as MGAH22) — currently in mid-stage trials for metastatic breast cancer and gastroesophageal cancer — and a second product, MGA271. Both are monoclonal antibodies. The cash from the IPO would also go toward advancing MacroGenics’ early-stage pipeline.
In August, another Maryland-based biotech firm, Intrexon Corp., filed for an initial public offering, and raised $160 million in the process.
Join our growing Slack community
Join 5,000 tech professionals and entrepreneurs in our community Slack today!
Donate to the Journalism Fund
Your support powers our independent journalism. Unlike most business-media outlets, we don’t have a paywall. Instead, we count on your personal and organizational contributions.
Despite Trump's actions and rhetoric, Ukrainian tech workers are laying stakes in the US
How tech and entrepreneurship can boost economic mobility
Meet our new reporter: Baltimore County native brings global experience to covering Maryland’s digital divide
